This is a multi-center, observational cohort study including patients with prior coronary artery bypass grafting (CABG) and ≥1 saphenous vein grafts (SVG) presenting with recurrent ischemic symptoms. Objective: to investigate the clinical outcomes in patients with prior CABG evaluated for bypass graft failure and progression of native coronary artery disease (CAD). Follow-up will be collected through national registry databases, electronic medical patient records and standardized telephonic assessment at 3 and 5 years follow-up.
Despite advances in secondary prevention, a wide variety of vascular grafts available, and evolving surgical techniques, long-term efficacy of CABG is hampered by bypass graft failure and native CAD progression. Therefore, patients with prior CABG often present with recurrent ischemic symptoms. Indeed, many prior CABG patients undergo repeat cardiac catheterization and require subsequent revascularization therapy. The clinical evaluation and diagnostic work-up of patients with recurrent angina after CABG is challenging. Patients with previous CABG are generally older, have a higher prevalence of cardiac risk factors and comorbidities, more extensive CAD, and complex atherosclerotic lesion morphology. Furthermore, current guideline recommendations on patient management are limited since post-CABG patients have often been underrepresented or excluded in large diagnostic and revascularization trials. This registry will include patients presenting with recurrent ischemic symptoms with a history of CABG and ≥1 SVGs that are referred to the Amsterdam University Medical Centers. Patients will be eligible for inclusion in the VIADUCT registry after consideration of in- and exclusion criteria. Subsequently, patients will be approached for study participation. Patients are free to refuse or to withdraw from participation in the registry at any moment. The primary objective is to investigate clinical outcomes in patients with recurrent symptoms who are evaluated for bypass graft failure and native CAD progression. In addition, results from non-invasive and invasive diagnostic tools that are used during clinical work-up to assess graft patency, the hemodynamic significance of native CAD progression, left ventricular function, and myocardial viability will be collected. We aim to evaluate the value of such tools to guide optimal repeat revascularization strategy.
Study Type
OBSERVATIONAL
Enrollment
500
Amsterdam University Medical Centers, Department of Cardiology
Amsterdam, Netherlands
RECRUITINGMajor adverse cardiovascular events (MACE)
The total number and specification of major adverse cardiac events (all-cause mortality, non-fatal myocardial infarction, or clinically driven repeat revascularization)
Time frame: 3 year follow-up
Saphenous vein graft failure
Failure rate and duration of graft patency following prior CABG procedure
Time frame: At the time of referral and during subsequent 3 and 5 years follow-up
Major Adverse Cardiac Events
Components of MACE (all-cause mortality, non-fatal myocardial infarction, or clinically driven repeat revascularization)
Time frame: 3 and 5 years follow-up
Procedural success and mortality in patients who underwent percutaneous coronary intervention of a saphenous vein graft
Procedural success defined by technical success and no major in-hospital complications (mortality, stroke, myocardial infarction, tamponade requiring centesis, emergency CABG/PCI, acute kidney failure requiring dialysis, vascular access site complication or major bleeding requiring transfusion or surgery)
Time frame: In hospital and during subsequent 3 and 5 years follow-up
Procedural success and mortality in patients who underwent percutaneous coronary intervention of a (bypassed) native coronary artery
Procedural success defined by technical success and no major in-hospital complications (mortality, stroke, myocardial infarction, tamponade requiring centesis, emergency CABG/PCI, acute kidney failure requiring dialysis, vascular access site complication or major bleeding requiring transfusion or surgery)
Time frame: In hospital and during subsequent 3 and 5 years follow-up
Quality of life assessed by the Canadian Cardiovascular Society (CCS) Grading Scale
Canadian Cardiovascular Society (CCS) Grading Scale measures whether patient have angina pectoris complaints, and to what extent patients experienced this. It uses a scale of 1-4 where 1 means angina pectoris (chest pain) only occurs with strenuous, rapid or prolonged exertion, and 4 means angina is present during little physical effort or even during rest.
Time frame: At baseline and during subsequent 3 and 5 years follow-up
Quality of life assessed by Rose dyspnea scale questionnaire (RDS)
Rose dyspnea scale questionnaire (RDS) measures dyspnea complaints, or shortness of breath. It consists of 4 questions about dyspnea complaints in the everyday life of patients. For every patient, a score is compiled of the highest limitation in daily life, resulting in a score of 0-4, where 0 means no dyspnea complaints and 4 means the patient has complaints during no or minimal physical effort.
Time frame: At baseline and during subsequent 3 and 5 years follow-up
Composite score of quality of life
Composite of all quality of life questionnaires, where all outcomes are summed to provide a total score
Time frame: At baseline and during subsequent 3 and 5 years follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.